GEOVAX LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
GEOVAX LABS, INC. (GOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $2.96 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-26.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2019-03-26
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.06, a 99.66% decline year-over-year.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $17.75.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.94, a 54.15% decline year-over-year.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2014-03-31 was $2.05, a 86.58% decline year-over-year.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2018 was $2.96, a 80.59% decline from fiscal 2017.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2017 was $15.25.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2015 was $1.50, a 20.63% decline from fiscal 2014.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2014 was $1.89, a 59.62% decline from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2018-12-31 | $2.96 10-K · filed 2019-03-26 | |||
| 2018-09-30 | $2.46 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $3.01 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $0.06 10-Q · filed 2018-05-03 | |||
| 2017-12-31 | $15.25 10-K · filed 2018-03-23 | |||
| 2017-09-30 | $17.75 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $17.75 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $17.75 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $1.50 10-K · filed 2016-03-16 | |||
| 2015-09-30 | $1.50 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $0.94 10-Q · filed 2015-08-04 | |||
| 2015-03-31 | $0.94 10-Q · filed 2015-05-14 | |||
| 2014-12-31 | $1.89 10-K · filed 2015-03-20 | |||
| 2014-09-30 | $1.89 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $1.91 10-Q · filed 2014-08-08 | |||
| 2014-03-31 | $2.05 10-Q · filed 2014-05-02 | |||
| 2013-12-31 | $4.68 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $4.86 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $4.59 10-Q · filed 2013-08-12 | |||
| 2013-03-31 | $15.28 10-Q · filed 2013-05-01 | |||
| 2012-12-31 | $4.02 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $4.60 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | $10.23 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |